Related Experiment Video
Updated: Jun 23, 2026
Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
Published on: May 22, 2018
Beta-blockers and sudden cardiac death
M J Kendall1, K P Lynch, A Hjalmarson
1Queen Elizabeth Hospital, Birmingham, United Kingdom.
Insights
Beta-blockers are highly effective in preventing sudden cardiac death and reducing mortality after heart attack. Despite perceived risks, their benefits in cardiovascular protection outweigh potential adverse effects, making them crucial for patient care.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Sudden cardiac death remains a significant concern in heart disease.
- Beta-blockers are a cornerstone therapy, but concerns about side effects persist.
Purpose of the Study:
- To evaluate the role of beta-blockers in preventing sudden cardiac death.
- To review and address perceived problems associated with beta-blocker therapy.
Main Methods:
- Comprehensive literature search of MEDLINE and EMBASE databases.
- Evaluation of over 400 original and review articles.
- Data extraction and review by multiple authors for accuracy.
Main Results:
- Beta-blockers are the most established and effective therapy for preventing sudden cardiac death.
- Evidence shows beta-blockers reduce atheroma formation, ventricular fibrillation risk, and cardiac mortality.
- Withholding beta-blockers due to perceived issues is often unwarranted and deprives patients of benefits.
Conclusions:
- Clinicians must recognize the significant impact of beta-blockers on morbidity and mortality.
- Initiating and maintaining beta-blocker therapy is crucial, even when faced with misinformation.
Objectives:
To 1) consider the problem of sudden death from heart disease and the role of beta-blockers and other agents in preventing sudden death and 2) review perceived problems with beta-blocker therapy, such as effects on blood lipids, complications in diabetes, and adverse effects on heart failure and quality of life.
Data Sources:
MEDLINE and EMBASE searches done from July 1994 on, and recognized texts.
Study Selection:
More than 400 original and review articles were evaluated, of which the most relevant were selected.
Data Extraction:
Data were extracted and reviewed by two authors. Accuracy was confirmed, when necessary, by the other authors.
Data Synthesis:
Of all of the therapies currently available for the prevention of sudden cardiac death, none is more established or more effective than beta-blockers. Indeed, the evidence that beta-blockers have a cardioprotective effect is compelling. They probably reduce the rate of atheroma formation; they reduce the risk for ventricular fibrillation in animal models of myocardial ischemia; they appear to reduce cardiac mortality in primary prevention trials; and they reduce mortality, particularly from sudden death, in patients who have had infarction. Moreover, withholding beta-blockers because of problems perceived to be associated with them is usually not warranted and may frequently prevent their use in those who will benefit most from them.
Conclusion:
Clinicians should reappraise the evidence for the significant effect of beta-blockers on morbidity and mortality, and they should recognize the importance of initiating and maintaining beta-blocker therapy when the less well-informed might suggest otherwise.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Heart Failure Drugs: β-Blockers